Another US setback for istradefylline as Valeant returns rights
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin's novel Parkinson's disease drug istradefylline has been hit by another setback in its long road to the US market after North American commercial partner Valeant Pharmaceuticals decided to discontinue a licensing agreement for the product.
You may also be interested in...
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
Pfizer Joins Singapore Initiative To Support Regional Startups
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Need a specific report? 1000+ reports available
Buy Reports